Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained a 'Perform' rating on Sage Therapeutics but has lowered the price target from $9 to $8.
October 30, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Oppenheimer has maintained its 'Perform' rating on Sage Therapeutics but reduced the price target from $9 to $8, indicating a slightly less optimistic outlook.
The lowering of the price target from $9 to $8 by Oppenheimer suggests a less optimistic view on Sage Therapeutics' future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100